Of interest, ACE inhibitors and ARBs increase levels of the protective hormone Ang-(1-7), which our group and others have shown contributes to the beneficial cardiometabolic effects of these therapies in animal models of cardiovascular diseases, obesity, and diabetes [12,13,14,15]. This evidence concerns the gene ANG and obesity due to melanocortin 4 receptor deficiency.